2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

ADC-Related Custom Services

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-141536
    PSMA-ALB-56
    		98.92%
    PSMA-ALB-56 is a PSMA-targeting radioligand designed by combining the glutamate-urea PSMA-binding entity and an albumin binder.
    PSMA-ALB-56
  • HY-156377
    Biotin-PEG7-Maleimide
    		99.42%
    Biotin-PEG7-Maleimide is a biotinylation reagent that reacts with thiol groups (SH). Biotin-PEG7-Maleimide can be used as Drug-Linker Conjugates for ADCs.
    Biotin-PEG7-Maleimide
  • HY-132161
    MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT
    		98.97%
    MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT is a Camptothecin-linker compound extracted from patent WO2019195665A1, example 4-1. MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT is a agent-linker conjugate for antibody-drug conjugate (ADC).
    MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT
  • HY-15742
    Vc-MMAD
    		99.96%
    Vc-MMAD consists the ADCs linker (Val-Cit) and potent tubulin inhibitor (MMAD). Vc-MMAD is a agent-linker conjugate for ADC.
    Vc-MMAD
  • HY-148245
    OH-Glu-Val-Cit-PAB-MMAE
    		99.92%
    OH-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (OH-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).
    OH-Glu-Val-Cit-PAB-MMAE
  • HY-126688
    Mal-C2-Gly3-EDA-PNU-159682
    Mal-C2-Gly3-EDA-PNU-159682, a agent-linker conjugate for ADC, consists a cleavable ADC linker Mal-C2-Gly3-EDA and a potent ADC cytotoxin PNU-159682.
    Mal-C2-Gly3-EDA-PNU-159682
  • HY-141147
    7-O-(Amino-PEG4)-paclitaxel
    		99.8%
    7-O-(Amino-PEG4)-paclitaxel is a PEG-class Drug-linker conjugates for ADC, containing a paclitaxel moiety and a amino group. The amine group is reactive with carboxylic acids, activated NHS esters, carbonyls (ketone, aldehyde) etc. 7-O-(Amino-PEG4)-paclitaxel can be used in the synthesis of Antibody-Drug Conjugates (ADCs).
    7-O-(Amino-PEG4)-paclitaxel
  • HY-156848
    Fmoc-GGFG-DXd
    		99.81%
    Fmoc-GGFG-DXd is a drug-linker conjugate for ADC. Fmoc-GGFG-DXd contains a ADC linker Fmoc-GGFG and a DNA topoisomerase I inhibitor DXd (HY-13631D).
    Fmoc-GGFG-DXd
  • HY-153601
    MC-VC-PAB-Cyclohexanediamine-Thailanstatin A
    MC-VC-PAB-Cyclohexanediamine-Thailanstatin A is a Spliceostatin (HY-16466) analog, and a drug-linker conjugates for ADC, consisting of ADC Cytotoxin Thailanstatin A (HY-129589) and cleavable ADC linker (MC-vc-PAB). MC-VC-PAB-Cyclohexanediamine-Thailanstatin A can be used for ADC synthesis.
    MC-VC-PAB-Cyclohexanediamine-Thailanstatin A
  • HY-153069
    GGFG-PAB-Exatecan
    		99.71%
    GGFG-PAB-Exatecan consists of an ADC toxin Exatecan (HY-13631) and a linker GGFG-PAB, and can be used as a drug-linker conjugate for the synthesis of ADC molecules.
    GGFG-PAB-Exatecan
  • HY-104025
    SPB
    		98.20%
    SPB is a agent-linker conjugate for ADC with potent anti-inflammatory activity by using Xanthotoxol, linked via the ADC linker.
    SPB
  • HY-19811
    Fmoc-Val-Cit-PAB-MMAE
    		98.89%
    Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC.
    Fmoc-Val-Cit-PAB-MMAE
  • HY-141860
    PSMA-Val-Cit-PAB-MMAE
    		Inhibitor 99.52%
    PSMA-Val-Cit-PAB-MMAE is a novel small-molecule PSMA-targeted conjugate based on the monomethyl auristatin E for the chemotherapy of prostate cancer.
    PSMA-Val-Cit-PAB-MMAE
  • HY-126491
    SPP-DM1
    SPP-DM1 is a agent-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker SPP.
    SPP-DM1
  • HY-147281
    BAY 1135626
    		99.19%
    BAY 1135626 is used to synthesize BAY 1129980, and use to anti-tumor research. BAY 1129980 is a Auristatin-based anti-C4.4A (LYPD3) antibody–agent conjugate (ADC), is used to non–small cell lung cancer (NSCLC) research.
    BAY 1135626
  • HY-131451
    Mc-Phe-Lys-PAB-MMAE
    Mc-Phe-Lys-PAB-MMAE (Compound 2) is a drug-linker conjugate for ADC, and can be used for synthesis of ADCs.
    Mc-Phe-Lys-PAB-MMAE
  • HY-W190943
    Azido-PEG4-Val-Cit-PAB-MMAE
    		99.43%
    Azido-PEG4-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH. Azido-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    Azido-PEG4-Val-Cit-PAB-MMAE
  • HY-153600
    GGFG-amide-glycol-amide-Exatecan
    		98.73%
    GGFG-amide-glycol-amide-Exatecan (Intermediate 2) is an Exatecan (HY-13631) derivative and can be used in the synthesis of antibody-drug conjugates (ADCs).
    GGFG-amide-glycol-amide-Exatecan
  • HY-19697
    Aminocaproyl-Val-Cit-PABC-MMAE
    		99.89%
    Aminocaproyl-Val-Cit-PABC-MMAE is an Drug-linker conjugate for ADC.
    Aminocaproyl-Val-Cit-PABC-MMAE
  • HY-156687
    GGFG-Eribulin
    GGFG-Eribulin (Compound GGFG) is a Drug-Linker Conjugates for ADC. GGFG-Eribulin consists of the ADC Cytotoxin Eribulin (HY-13442) and a linker. GGFG-Eribulin can be used for synthesis of ADCs.
    GGFG-Eribulin
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.